JP2004530721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004530721A5 JP2004530721A5 JP2003508341A JP2003508341A JP2004530721A5 JP 2004530721 A5 JP2004530721 A5 JP 2004530721A5 JP 2003508341 A JP2003508341 A JP 2003508341A JP 2003508341 A JP2003508341 A JP 2003508341A JP 2004530721 A5 JP2004530721 A5 JP 2004530721A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- pharmaceutically active
- active ingredient
- mini
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013268 sustained release Methods 0.000 claims 41
- 239000012730 sustained-release form Substances 0.000 claims 41
- 239000007943 implant Substances 0.000 claims 27
- 239000004480 active ingredient Substances 0.000 claims 24
- 230000036765 blood level Effects 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 14
- 239000008188 pellet Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- -1 antidiabetics Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 239000000463 material Substances 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003096 antiparasitic agent Substances 0.000 claims 2
- 229940125687 antiparasitic agent Drugs 0.000 claims 2
- 230000004323 axial length Effects 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 150000002596 lactones Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940124325 anabolic agent Drugs 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 230000001165 anti-coccidial effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124346 antiarthritic agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000000560 biocompatible material Substances 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003633 blood substitute Substances 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 239000003576 central nervous system agent Substances 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229910021485 fumed silica Inorganic materials 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000007952 growth promoter Substances 0.000 claims 1
- 239000003630 growth substance Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000002874 hemostatic agent Substances 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 229960002418 ivermectin Drugs 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000012763 reinforcing filler Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 239000002210 silicon-based material Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR6025A AUPR602501A0 (en) | 2001-06-29 | 2001-06-29 | Sustained release pharmaceutical composition |
| AUPR6025 | 2001-06-29 | ||
| PCT/AU2002/000865 WO2003002102A1 (en) | 2001-06-29 | 2002-07-01 | Sustained release pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004530721A JP2004530721A (ja) | 2004-10-07 |
| JP2004530721A5 true JP2004530721A5 (enExample) | 2005-12-22 |
| JP4800570B2 JP4800570B2 (ja) | 2011-10-26 |
Family
ID=3829991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003508341A Expired - Fee Related JP4800570B2 (ja) | 2001-06-29 | 2002-07-01 | 徐放性医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040241204A1 (enExample) |
| EP (1) | EP1411904A4 (enExample) |
| JP (1) | JP4800570B2 (enExample) |
| CN (1) | CN1731988A (enExample) |
| AU (2) | AUPR602501A0 (enExample) |
| BR (1) | BR0210631A (enExample) |
| CA (1) | CA2452030A1 (enExample) |
| CO (1) | CO5540373A2 (enExample) |
| NZ (1) | NZ529859A (enExample) |
| WO (1) | WO2003002102A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129728A1 (en) * | 2001-09-11 | 2005-06-16 | Martinod Serge R. | Sustained release pharmaceutical composition |
| CN1638747A (zh) * | 2002-01-24 | 2005-07-13 | 斯玛特药物系统公司 | 持续释放药物组合物 |
| US20080044450A1 (en) * | 2004-05-31 | 2008-02-21 | Malcolm Brandon | Sustained Release Composition |
| WO2005123120A1 (en) * | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
| AU2005253646B2 (en) * | 2004-06-16 | 2011-09-15 | Virbac Corporation | Sustained release vaccine composition |
| EP2594259A1 (en) | 2004-08-04 | 2013-05-22 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| EP1859788A1 (en) * | 2006-05-24 | 2007-11-28 | Abbott GmbH & Co. KG | Production of enveloped pharmaceutical dosage forms |
| NZ552290A (en) * | 2006-12-21 | 2009-05-31 | Bomac Research Ltd | Tablet fomulation |
| BRPI0705822A2 (pt) * | 2007-10-25 | 2009-06-23 | Schering Plough Saude Animal Ltda | formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| CN102215901B (zh) * | 2008-11-07 | 2014-12-03 | 联合生物医学系统有限公司 | 用于治疗和/或预防疾病的装置和方法 |
| MX2011009678A (es) | 2009-03-17 | 2011-09-30 | Intervet Int Bv | Sistema de suministro de farmaco de lactona macrociclica. |
| WO2011151386A1 (en) * | 2010-06-01 | 2011-12-08 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
| HRP20190562T1 (hr) | 2010-07-30 | 2019-06-14 | CEVA Santé Animale SA | Sastavi za liječenje zaraze srčanim crvom |
| JP5696279B2 (ja) * | 2010-12-01 | 2015-04-08 | 学校法人自治医科大学 | 長期徐放型薬剤硬膜外腔留置システム |
| PL2785719T3 (pl) | 2011-12-02 | 2018-03-30 | Merial, Inc. | Długodziałające wstrzykiwalne postaci moksydektyny i nowe postaci krystaliczne moksydektyny |
| US20130190839A1 (en) * | 2012-01-20 | 2013-07-25 | Jane Rapsey | Drug delivery using a sacrificial host |
| WO2014160026A2 (en) * | 2013-03-14 | 2014-10-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof |
| AU2013209343B1 (en) * | 2013-05-14 | 2014-04-24 | Activesignal Holding Limited | Device for the Treatment of Bone Conditions |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| ITUB20153652A1 (it) | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| JP2021528452A (ja) * | 2018-06-25 | 2021-10-21 | タイタン ファーマシューティカルズ インコーポレイテッド | インプラントとして使用するための装填可能な多孔質構造 |
| WO2020181340A1 (en) * | 2019-03-14 | 2020-09-17 | Palmaya Pty Ltd | Treatment of inflammatory diseases of the central nervous system |
| CN110559431B (zh) * | 2019-10-11 | 2023-02-28 | 南京农业大学 | 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用 |
| CA3201057A1 (en) | 2020-12-08 | 2022-06-16 | Mark Christopher LAY | Improvements to devices and methods for delivery of substances to animals |
| US20240238226A1 (en) * | 2021-03-09 | 2024-07-18 | Adnan I. Qureshi | Implantable sustained release device and a method of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US4053580A (en) * | 1975-01-01 | 1977-10-11 | G. D. Searle & Co. | Microsealed pharmaceutical delivery device |
| US4331652A (en) * | 1979-09-12 | 1982-05-25 | Eli Lilly And Company | Controlled release parasitic formulations and method |
| US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| US5028430A (en) * | 1987-05-08 | 1991-07-02 | Syntex (U.S.A.) Inc. | Delivery systems for the controlled administration of LHRH analogs |
| ATE90203T1 (de) * | 1989-03-17 | 1993-06-15 | Pitman Moore Inc | Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen. |
| KR0141583B1 (ko) * | 1989-06-21 | 1998-06-15 | 윌리암 엠. 잭슨 | 신경병 치료장치 |
| FR2653338B1 (fr) * | 1989-10-23 | 1994-06-10 | Dow Corning Sa | Formulation pour des pansements a liberation prolongee de medicament et son utilisation. |
| EP0542915A1 (en) * | 1990-08-09 | 1993-05-26 | Endocon, Inc. | Multiple drug delivery system |
| NZ239370A (en) * | 1990-08-22 | 1994-04-27 | Merck & Co Inc | Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone |
| US5211951A (en) * | 1991-07-24 | 1993-05-18 | Merck & Co., Inc. | Process for the manufacture of bioerodible poly (orthoester)s and polyacetals |
| JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
| JP3720386B2 (ja) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | 薬物放出制御製剤 |
| FR2745180B1 (fr) * | 1996-02-23 | 1998-05-07 | Dow Corning Sa | Procede de fabrication de dispositifs a liberation controlee |
| BR9812385A (pt) * | 1997-09-23 | 2000-09-12 | Pfizer | Formulações parasiticidas |
| AUPP279698A0 (en) * | 1998-04-03 | 1998-04-30 | Sunscape Developments Limited | Sustained release formulation |
| IL140899A0 (en) * | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
| GB9816132D0 (en) * | 1998-07-24 | 1998-09-23 | Norbrook Lab Ltd | Non-aqueous anthelmintic composition |
| AU5532699A (en) * | 1998-09-05 | 2000-03-27 | Seung Jin Lee | Biodegradable particulate polymeric preparation and process for producing thereof |
| US6645192B2 (en) * | 1998-09-30 | 2003-11-11 | Ivy Animal Health, Inc. | Pellet implant system for immediate and delayed release of antiparasitic drug |
| WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| AU6526100A (en) * | 1999-08-06 | 2001-03-05 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
| TW524696B (en) * | 1999-11-10 | 2003-03-21 | Sumitomo Pharma | Sustained-release drug formulations |
| WO2001037811A1 (en) * | 1999-11-22 | 2001-05-31 | Akzo Nobel N.V. | Composition allowing predefined and controlled release of active ingredient, preparation thereof and use |
| US20020131988A1 (en) * | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
-
2001
- 2001-06-29 AU AUPR6025A patent/AUPR602501A0/en not_active Abandoned
-
2002
- 2002-07-01 AU AU2002344685A patent/AU2002344685B2/en not_active Ceased
- 2002-07-01 US US10/482,336 patent/US20040241204A1/en not_active Abandoned
- 2002-07-01 WO PCT/AU2002/000865 patent/WO2003002102A1/en not_active Ceased
- 2002-07-01 EP EP02742515A patent/EP1411904A4/en not_active Ceased
- 2002-07-01 CN CNA028131525A patent/CN1731988A/zh active Pending
- 2002-07-01 JP JP2003508341A patent/JP4800570B2/ja not_active Expired - Fee Related
- 2002-07-01 BR BR0210631-0A patent/BR0210631A/pt not_active IP Right Cessation
- 2002-07-01 NZ NZ529859A patent/NZ529859A/en not_active IP Right Cessation
- 2002-07-01 CA CA002452030A patent/CA2452030A1/en not_active Abandoned
-
2003
- 2003-12-23 CO CO03112102A patent/CO5540373A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004530721A5 (enExample) | ||
| JP2004535473A5 (enExample) | ||
| JP4913321B2 (ja) | 徐放性医薬組成物 | |
| EP0301856B1 (en) | Delivery system | |
| JP4459444B2 (ja) | 多層構造を有する放出制御製剤 | |
| JP4800570B2 (ja) | 徐放性医薬組成物 | |
| EP0981327A2 (en) | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors | |
| JPWO1999062501A1 (ja) | 多層構造を有する放出制御製剤 | |
| JP2005523077A (ja) | 抗肉芽腫剤を形成する特性を備えた胃瘻造設術又は空腸造瘻術に使用される薄型の組合せ装置 | |
| JP2003517014A (ja) | 即放性および徐放性成分を含有する医薬インプラントおよび投与方法 | |
| AU2002344686A1 (en) | Sustained release delivery system | |
| JP2005505557A (ja) | 持続放出医薬組成物の調製 | |
| US20050118271A1 (en) | Polytartrate composition | |
| JP4753471B2 (ja) | 長期薬物徐放性製剤 | |
| JP2021529747A (ja) | 親油性又は両親媒性医薬物質の放出のためのインプラント | |
| JP2005517653A5 (enExample) | ||
| JP2005517653A (ja) | Ｘ線不透過性徐放性医薬器具 | |
| AU2003201410B2 (en) | Sustained release pharmaceutical composition | |
| JP2005522418A5 (enExample) | ||
| Cardinal et al. | Drug delivery in veterinary medicine | |
| Unde et al. | Manoeuvring the innovative drug delivery systems for veterinary therapeutics: Present day demand | |
| JPH09502182A (ja) | 疎水性剤を含有するディスペンサー | |
| AU2002344687A1 (en) | Treatment of parasitic disease | |
| WO1993017662A1 (en) | Improved implants | |
| WO1992018101A1 (en) | Vaginal drug delivery device |